A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

Recruiting now · Phase 2

Conditions studied: Meningioma

In brief

This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.

Key facts

Study ID

NCT07533942

Run by

Jazz Pharmaceuticals

People needed

30

Starts

2026-07-16

Expected to finish

2031-10-16

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• NYU- Langone Health — New York, New York, United States (enrolling)
• Sutter Health — San Francisco, California, United States
• Louisiana State University — New Orleans, Louisiana, United States
• Mass General — Boston, Massachusetts, United States
• University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.